Famotidine
- Generic Name
- Famotidine
- Brand Names
- Duexis, Duo Fusion, Fluxid, Good Sense Acid Reducer, Pepcid, Pepcid Complete, Zantac Reformulated Aug 2022
- Drug Type
- Small Molecule
- Chemical Formula
- C8H15N7O2S3
- CAS Number
- 76824-35-6
- Unique Ingredient Identifier
- 5QZO15J2Z8
- Background
Famotidine is a competitive histamine-2 (H) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H receptor antagonists, famotidine displays high selectivity to...
- Indication
Famotidine is indicated in pediatric and adult patients (with the bodyweight of 40 kg and above) for the management of active duodenal ulcer (DU), active gastric ulcer, symptomatic non-erosive gastroesophageal reflux disease (GERD), and erosive esophagitis due to GERD, diagnosed by biopsy.
...
- Associated Conditions
- Chronic Back Pain, Duodenal Ulcer, Erosive Esophagitis, Extra-Articular Rheumatism, Gastritis, Heartburn, Helicobacter Pylori Infection, Multiple Endocrine Neoplasia, Muscle Spasms, Nonspecific Pain Post Traumatic Injury, Osteoarthritis (OA), Postoperative pain, Stress Ulcers, Symptomatic Non-erosive Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Active Gastric ulcer, Acute Duodenal Ulcers, Gastrointestinal ulceration, Pathological hypersecretory conditions
- Associated Therapies
- -
A Study Assessing the Drug Levels, Drug Effects, and Safety of BMS-986322 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 171
- Registration Number
- NCT04175925
- Locations
- 🇺🇸
ICON (LPRA) - Lenexa, Lenexa, Kansas, United States
A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets
- Conditions
- Interventions
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2021-01-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT04065932
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT03805932
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease
- Conditions
- Interventions
- First Posted Date
- 2018-09-12
- Last Posted Date
- 2022-09-21
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT03667703
- Locations
- 🇺🇸
Boston Children's Hospital, Boston, Massachusetts, United States
Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-03-01
- Last Posted Date
- 2018-09-06
- Lead Sponsor
- Eisai Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT03451110
- Locations
- 🇺🇸
Worldwide Clinical Trials, San Antonio, Texas, United States
Study of Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology
- Conditions
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT03330028
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986263 in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2017-05-05
- Last Posted Date
- 2018-01-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT03142165
- Locations
- 🇺🇸
Wcct Global, Llc, Cypress, California, United States
Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-04-11
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- University of Chicago
- Target Recruit Count
- 76
- Registration Number
- NCT03107182
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2016-05-05
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 357
- Registration Number
- NCT02763969
- Locations
- 🇦🇺
Local Institution, Melbourne, Australia
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02684799
- Locations
- 🇺🇸
SeaView Research, Inc., Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.